Menu
Menu
Alembic Pharmaceuticals has secured USFDA approval for its generic version of Brexpiprazole Tablets, a treatment for major depressive disorder and schizophrenia. This approval opens the door to a $2 billion market, providing a more affordable option for patients while strengthening Alembic’s position in the generics sector.